Order of Discontinuation of Glucose-lowering Medications following Bariatric Surgery

According to the American Society for Metabolic and Bariatric Surgery, the estimated number of bariatric surgeries performed in 2018 was 252,000 which represents a 91% increase from 113,000 surgeries in 2006.1,2 In addition to the obesity epidemic, one potential reason for this increasing trend is the positive impact of bariatric surgery on Type 2 diabetes mellitus (T2DM). Bariatric surgery can be considered in patients with T2DM who have a body mass index (BMI) of ≥40 kg/m2, BMI between 35.0-39.9 kg/m2 with hyperglycemia that is inadequately controlled by lifestyle and optimal glucose-lowering medications (GLMs), or BMI of 30.0-34.9 kg/m2 with hyperglycemia that is inadequately controlled despite optimal treatment with either oral or injectable GLMs.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research